Stock Alert: TrueCar Rises As Demand Returns

By RTTNews Staff Writer ✉ | Published: 6/19/2020 4:19 AM ET

Shares of TrueCar, Inc. (TRUE), an automotive pricing and information website for new and used car buyers, jumped $0.23 or 8.21% Thursday after-hours after the company revealed that vehicle demand has returned in May and continues rising in June.

In March, vehicle demand was negative 41% and it has bounced back to 2% in May and further increased to 19% during the first 15 days of June.

Thursday, TrueCar stock was up $0.07 or 2.56% before closing t $2.80. It has traded in the range of $1.98-$5.59 in the last 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks PDUFA COVID 19 Vaccines peanut allergy Trelegy Ellipta Pain drug exertional heatstroke allergic conjunctivitis

Biotech Stocks Facing FDA Decision In August 2020

New Drugs Approved In June

Coronavirus Vaccines In Human Trials COVID19 Antibodies Spike Protein US Operation Warp Speed

Tracking Coronavirus Vaccines In Human Trials

Editors Pick

Berkshire Q2 Profit Up 87%, But Operating Profit Down 10%

Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent.

Twitter In Preliminary Talks To Buy TikTok's U.S. Operations : Report

Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok.

Pfizer Signs Deal To Boost Supply Of Gilead's Remdesivir For COVID-19 Patients

Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.